Skip to content

Study · Case report or series · n = 1 · 2025

7 results

Semaglutide, a Long-Acting GLP-1 Analogue, for the Management of Early-Onset Obesity due to MC4R Defect: A Case Report.

Gokul PR, Apperley L, Parkinson J, Clark K, Lund K, Owens M, Senniappan S

Hormone research in paediatrics23 Feb 2024Cited by 10 (Europe PMC)

PMID38402868 (opens in a new tab)DOI10.1159/000537921 (opens in a new tab)PepBankPUB-38402868
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 13-year-old boy with heterozygous MC4R(E61K)-related severe obesity, semaglutide lowered BMI from 56.9 kg/m2 (+4.19 SDS) to 52.2 kg/m2 (+4.08 SDS) over 12 weeks.

    In plain wordsIn a 13-year-old boy with MC4R-related obesity, semaglutide was followed by lower BMI after 12 weeks.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.25 mg weekly to 1 mg weekly · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    BMI
    56.9 kg/m2
    before semaglutide; +4.19 SDS
    BMI
    52.2 kg/m2
    12 weeks; +4.08 SDS

    Source sentences

    Summary
    Over the course of 12 weeks, his BMI decreased to 52.2 kg/m2 (+4.08 SDS) and weight dropped to 176.8 kg (+14.76 SDS, body fat: 52.7%).
    3 context sentences
    Summary · context
    Despite intense multidisciplinary lifestyle interventions, he continued to gain weight, reaching a peak weight of 187.5 kg (+16.65 standard deviation score [SDS]), body mass index (BMI) of 56.9 kg/m2 (+4.19 SDS), and body fat of 63.9% at the age of 13 years.
    Summary · context
    He was commenced on semaglutide subcutaneous injection at a dose of 0.25 mg weekly, gradually increasing to the maximum dose of 1 mg weekly.
    Summary · context
    Diagnostic investigations revealed insulin resistance and dyslipidaemia, while genetic testing confirmed a heterozygous mutation in MC4R (E61K), inherited from his mother.
  2. 02HumanCase report or seriesEfficacy outcome

    In a 13-year-old boy with heterozygous MC4R(E61K)-related severe obesity, semaglutide lowered body weight from 187.5 kg (+16.65 SDS) to 176.8 kg (+14.76 SDS) over 12 weeks.

    In plain wordsIn a 13-year-old boy with MC4R-related obesity, semaglutide was followed by lower body weight after 12 weeks.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.25 mg weekly to 1 mg weekly · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Body weight
    187.5 kg
    before semaglutide; +16.65 SDS
    Body weight
    176.8 kg
    12 weeks; +14.76 SDS

    Source sentences

    Summary
    Over the course of 12 weeks, his BMI decreased to 52.2 kg/m2 (+4.08 SDS) and weight dropped to 176.8 kg (+14.76 SDS, body fat: 52.7%).
    3 context sentences
    Summary · context
    Despite intense multidisciplinary lifestyle interventions, he continued to gain weight, reaching a peak weight of 187.5 kg (+16.65 standard deviation score [SDS]), body mass index (BMI) of 56.9 kg/m2 (+4.19 SDS), and body fat of 63.9% at the age of 13 years.
    Summary · context
    He was commenced on semaglutide subcutaneous injection at a dose of 0.25 mg weekly, gradually increasing to the maximum dose of 1 mg weekly.
    Summary · context
    Diagnostic investigations revealed insulin resistance and dyslipidaemia, while genetic testing confirmed a heterozygous mutation in MC4R (E61K), inherited from his mother.
  3. 03HumanCase report or seriesEfficacy outcome

    In a 13-year-old boy with heterozygous MC4R(E61K)-related severe obesity, semaglutide was followed by body fat decreasing from 63.9% to 52.7% over 12 weeks.

    In plain wordsIn a 13-year-old boy with MC4R-related obesity, body fat was lower after 12 weeks of semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody fat
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.25 mg weekly to 1 mg weekly · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Body fat
    63.9%
    before semaglutide
    Body fat
    52.7%
    12 weeks

    Source sentences

    Summary
    Over the course of 12 weeks, his BMI decreased to 52.2 kg/m2 (+4.08 SDS) and weight dropped to 176.8 kg (+14.76 SDS, body fat: 52.7%).
    3 context sentences
    Summary · context
    Despite intense multidisciplinary lifestyle interventions, he continued to gain weight, reaching a peak weight of 187.5 kg (+16.65 standard deviation score [SDS]), body mass index (BMI) of 56.9 kg/m2 (+4.19 SDS), and body fat of 63.9% at the age of 13 years.
    Summary · context
    He was commenced on semaglutide subcutaneous injection at a dose of 0.25 mg weekly, gradually increasing to the maximum dose of 1 mg weekly.
    Summary · context
    Diagnostic investigations revealed insulin resistance and dyslipidaemia, while genetic testing confirmed a heterozygous mutation in MC4R (E61K), inherited from his mother.
  4. 04HumanCase report or seriesEfficacy outcome

    In a 13-year-old boy with MC4R-related severe obesity, semaglutide was followed by 5.7% weight loss at 3 months.

    In plain wordsIn a 13-year-old boy with MC4R-related obesity, semaglutide was followed by 5.7% weight loss at 3 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss at 3 months
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.25 mg weekly to 1 mg weekly · subcutaneousAs given in this study (human).

    Measurements

    Weight loss
    5.7%
    3-month review

    Source sentences

    Summary
    At the 3-month and 12-month reviews post-treatment, he achieved weight loss of 5.7% and 11%, respectively.
    3 context sentences
    Summary · context
    A 13-year-old boy with a history of excessive weight gain since infancy was referred to the specialised weight management team.
    Summary · context
    Diagnostic investigations revealed insulin resistance and dyslipidaemia, while genetic testing confirmed a heterozygous mutation in MC4R (E61K), inherited from his mother.
    Summary · context
    He was commenced on semaglutide subcutaneous injection at a dose of 0.25 mg weekly, gradually increasing to the maximum dose of 1 mg weekly.
  5. 05HumanCase report or seriesEfficacy outcome

    In a 13-year-old boy with MC4R-related severe obesity, semaglutide was followed by 11% weight loss at 12 months.

    In plain wordsIn a 13-year-old boy with MC4R-related obesity, semaglutide was followed by 11% weight loss at 12 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss at 12 months
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.25 mg weekly to 1 mg weekly · subcutaneousAs given in this study (human).

    Measurements

    Weight loss
    11%
    12-month review

    Source sentences

    Summary
    At the 3-month and 12-month reviews post-treatment, he achieved weight loss of 5.7% and 11%, respectively.
    3 context sentences
    Summary · context
    A 13-year-old boy with a history of excessive weight gain since infancy was referred to the specialised weight management team.
    Summary · context
    Diagnostic investigations revealed insulin resistance and dyslipidaemia, while genetic testing confirmed a heterozygous mutation in MC4R (E61K), inherited from his mother.
    Summary · context
    He was commenced on semaglutide subcutaneous injection at a dose of 0.25 mg weekly, gradually increasing to the maximum dose of 1 mg weekly.
  6. 06HumanCase report or seriesEfficacy outcome

    In a 13-year-old boy with MC4R-related severe obesity, semaglutide was followed by a quality-of-life score increase from 35.95 to 60.36 at 12 months.

    In plain wordsIn a 13-year-old boy with MC4R-related obesity, quality-of-life scores were higher at the 12-month review following semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseQuality of life questionnaire score
    Study

    n = 1

    Outcome group
    Quality of life · Whole body
    Studied dose
    0.25 mg weekly to 1 mg weekly · subcutaneousAs given in this study (human).

    Measurements

    Quality of life questionnaire score
    35.95
    before treatment
    Quality of life questionnaire score
    60.36
    12-month review

    Source sentences

    Summary
    The quality of life questionnaire showed improved scores from 35.95 to 60.36 at 12-month review, indicating enhanced well-being.
    3 context sentences
    Summary · context
    A 13-year-old boy with a history of excessive weight gain since infancy was referred to the specialised weight management team.
    Summary · context
    Diagnostic investigations revealed insulin resistance and dyslipidaemia, while genetic testing confirmed a heterozygous mutation in MC4R (E61K), inherited from his mother.
    Summary · context
    He was commenced on semaglutide subcutaneous injection at a dose of 0.25 mg weekly, gradually increasing to the maximum dose of 1 mg weekly.
  7. 07HumanCase report or seriesEfficacy outcome

    In a 13-year-old boy with MC4R-related severe obesity, semaglutide was followed by improved continuous-glucose-monitor time in range.

    In plain wordsIn a 13-year-old boy with MC4R-related obesity, time in the target glucose range improved after semaglutide.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedTime in range
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.25 mg weekly to 1 mg weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The continuous glucose monitor demonstrated an improvement in time in range.
    3 context sentences
    Summary · context
    A 13-year-old boy with a history of excessive weight gain since infancy was referred to the specialised weight management team.
    Summary · context
    Diagnostic investigations revealed insulin resistance and dyslipidaemia, while genetic testing confirmed a heterozygous mutation in MC4R (E61K), inherited from his mother.
    Summary · context
    He was commenced on semaglutide subcutaneous injection at a dose of 0.25 mg weekly, gradually increasing to the maximum dose of 1 mg weekly.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.